LIDODERM® has been trusted by healthcare professionals for more than a decade to treat after-shingles pain -- see why.
The American Academy of Neurology (subcommittee) recommends LIDODERM based on1:
-
Effective in reducing after-shingles pain
-
Level A, class I and II dataI
-
Good strength of clinical evidence from well-designed trials
-
Low level of side effects
The Fourth International Conference on the Mechanisms and Treatment of Neuropathic Pain recommends LIDODERM first-line based on2,II:
-
Consistently effective in randomized, controlled clinical trials
-
Excellent safety and tolerability
-
Statistically significant greater pain relief vs placebo
-
An adequate 2-week trial, no dosage adjustments necessary
Council members of the International Association for the Study of Pain (in an independent analysis) recommend LIDODERM based on3:
-
Effective in treating localized pain of after-shingles pain
-
Side effect profile (few side effects)
-
Design of clinical trials
-
Use alone or with other medications
Based on a review of the literature by Argoff et al,
Targeting various PHN mechanisms with multiple agents may result in better treatment
outcomes4.
I Level A rating establishes a therapy as effective, ineffective, or harmful for
the given condition in the specified population based on at least 1 convincing class
I study or at least 2 consistent, convincing class II studies. Class II studies
are prospective, matched-group, cohort studies in representative populations with
masked outcome assessments that meet predefined criteria or randomized, controlled
trials in representative populations that lack one of the predefined criteria.
II Endo Pharmaceuticals provided an unrestricted educational grant to the University
of Rochester Office of Professional Education (Rochester, NY) to support a meeting
on the treatment of neuropathic pain. All authors, except Dr Max, received an honorarium
from the University of Rochester. Separate from this meeting, the following have
received consulting or other financial support from Endo Pharmaceuticals: Drs Argoff,
Bennett, Dworkin, Farrar, Galer, Loeser, Max, Rowbotham, Turk, and Wallace.
Resources